Year: 2023
Type: editorial
Abstract: Immunometabolism of T cells in skin infection, autoimmunity and cancer biologySubsets of immune cells exhibit distinct functional capacities and utilize different metabolic pathways to orchestrate their differentiation, activation, function, plasticity, and survival (1).Understanding how metabolic reprogramming instructs T-cell subsets not only represents crucial opportunities to delineate new avenues in their biology, but also provides opportunities for tuning T-cell function for therapeutic purposes (2).In this Research Topic, the authors have reviewed current investigations and understanding of the immunometabolism of T-cell subsets and elucidated a series of metabolic reprogramming strategies for enhancing antitumor function, improving transplantation immunity, and ameliorating autoimmune diseases.Several obstacles, including inadequate immune infiltrate, a suppressive tumor microenvironment (TME), tumor heterogeneity and evolution, and exhausted effector cells, pose significant challenges to the sustained antitumor ability of genetically engineered T cells in promising T cell receptor targeting (TCR-T) therapies for solid tumors (3, 4).To overcome these obstacles, Mao provided a multidimensional review of current metabolic reprogramming strategies. These strategies include pharmacologic inhibition of glucose-6- phosphate dehydrogenase (G6PD) and glutamine transporters to enhance T cell cytotoxicity, treatment with Diclofenac to inhibit monocarboxylate transporter 1 and 4 (MCT1 and MCT4), indoleamine 2,3-dioxygenase (IDO) inhibitors such as Epacadostat to reduce kynurenine (5, 6). As metabolism is a matter of balance, perturbations must be timed precisely to yield the desired phenotype. Mao emphasized that, due to the complexity of targeting mTORC1, targeting mTORC2 could emerge as a potential alternative to Frontiers in Immunology frontiersin.
Source: Frontiers in Immunology
Language: English
Topic: T-cell and B-cell Immunology
Subfield: Immunology
Field: Immunology and Microbiology
Domain: Life Sciences
Open Access status: gold
Estimated APC paid: $3,295
Awards: G5886182674, G6769183748
OpenAlex ID: W4382653737